Preventive Care
- Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)
As we dig deeper into the reduction in cardiovascular deaths seen with some newer drugs, several questions arise.
- Diabetes management: Beyond hemoglobin A1c
Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.
- ACE inhibitors and ARBs: Managing potassium and renal function
Concern about hyperkalemia and a decline in renal function has led to underuse of these drugs.
- ACE inhibitor and ARB therapy: Practical recommendations
Inhibitors of the renin-angiotensin-aldosterone system are cornerstones of therapy of cardiovascular disease.
- Disparities in cardiovascular care: Past, present, and solutions
Cardiovascular disease makes no distinction in race, sex, age, or socioeconomic status, and neither should clinicians.
- Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
Consider it in those with granulomatosis with polyangiitis or pulmonary disease, or those on high-dose steroids.
- The return of measles—an unnecessary sequel
Why are we having such a tough time convincing people to get routine vaccines for themselves and for their kids?
- Colorectal cancer screening: Choosing the right test
The choice depends on patient preference, family history, and the likelihood of compliance.
Measles: A dangerous vaccine-preventable disease returnsVaccine refusal and global unrest have led to an alarming upswing in measles cases.
